Search

Your search keyword '"Cupissol D"' showing total 420 results
Start Over Author "Cupissol D"
420 results on '"Cupissol D"'

1. Beneath HMGA2 alterations in pleomorphic adenomas: Pathological, immunohistochemical, and molecular insights

Author

Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Grayeli, A.Bozorg, Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Clatot, F., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F.R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Saint Guily, J. Lacau, Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Cardon, A.Lasne, Le Tourneau, C., Lefebvre, G., Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A., Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Dang, N. Pham, Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., J.-M.Prades, Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Siegfried, A., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., J.Thariat, David, M. Timar, Timochenko, A., Toussaint, B., Coste, E. Uro, Valette, G., Van den Abbele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., Wong, S., Alsugair, Ziyad, Lépine, Charles, Descotes, Françoise, Lanic, Marie-Delphine, Pissaloux, Daniel, Tirode, Franck, Lopez, Jonathan, Céruse, Philippe, Philouze, Pierre, Fieux, Maxime, Wassef, Michel, Baglin, Anne-Catherine, Mihaela, Onea, Castain, Claire, Sudaka, Anne, Uro-Coste, Emmanuelle, Champagnac, Anne, Costes-Martineau, Valérie, Laé, Marick, and Benzerdjeb, Nazim

Published
2024
Full Text
View/download PDF

2. Characterization of a Molecularly Distinct Subset of Oncocytic Pleomorphic Adenomas/Myoepitheliomas Harboring Recurrent ZBTB47-AS1: PLAG1 Gene Fusion

Author

Alsugair, Ziyad, Perrot, Jimmy, Descotes, Françoise, Lopez, Jonathan, Champagnac, Anne, Pissaloux, Daniel, Castain, Claire, Onea, Mihaela, Céruse, Philippe, Philouze, Pierre, Lépine, Charles, Lanic, Marie-Delphine, Laé, Marick, Costes-Martineau, Valérie, Benzerdjeb, Nazim, Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Grayeli, A. Bozorg, Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Clatot, F., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F. R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Saint Guily, J. Lacau, Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Cardon, A. Lasne, Le Tourneau, C., Lefebvre, G, Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A, Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Dang, N. Pham, Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., Prades, J.-M., Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., Thariat, J., David, M. Timar, Timochenko, A., Toussaint, B., Coste, E. Uro, Valette, G., Van den Abbele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., and Wong, S.

Published
2024
Full Text
View/download PDF

3. Impact of facial nerve resection in parotid cancer abutting the facial nerve without preoperative paralysis: A multicentric propensity score-based analysis

Author

Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Bettoni, J., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Bozorg Grayeli, A., Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Classe, M., Clatot, F., Colin, E., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Espitalier, F., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F.R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Lacau Saint Guily, J., Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Lasne Cardon, A., Le Tourneau, C., Lefebvre, G., Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A., Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Pham Dang, N., Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., Prades, J.-M., Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., Thariat, J., Timar David, M., Timochenko, A., Toussaint, B., Uro Coste, E., Valette, G., Van den Abbeele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., Wong, S., Chatelet, Florian, Chevret, Sylvie, Fakhry, Nicolas, Even, Caroline, Malard, Olivier, de Monès, Erwan, Saroul, Nicolas, Mouawad, François, de Boutray, Marie, Mauvais, Olivier, Vergez, Sébastien, Evrard, Diane, Righini, Christian, Schultz, Philippe, Baudouin, Robin, Poissonnet, Gilles, Atallah, Sarah, Haroun, Fabienne, Morinière, Sylvain, Evrard, Camille, Philouze, Pierre, Paasche, Agnès, Lesnik, Maria, Lelonge, Yann, Herman, Philippe, and Verillaud, Benjamin

Published
2024
Full Text
View/download PDF

4. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial

Author

Le Cesne, A., Blay, J.-Y., Cupissol, D., Italiano, A., Delcambre, C., Penel, N., Isambert, N., Chevreau, C., Bompas, E., Bertucci, F., Chaigneau, L., Piperno-Neumann, S., Salas, S., Rios, M., Guillemet, C., Bay, J.-O., Ray-Coquard, I., Haddag, L., Bonastre, J., Kapso, R., Fraslin, A., Bouvet, N., Mir, O., and Foulon, S.

Published
2021
Full Text
View/download PDF

5. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

Author

Pautier, P., Floquet, A., Chevreau, C., Penel, N., Guillemet, C., Delcambre, C., Cupissol, D., Selle, F., Isambert, N., Piperno-Neumann, S., Saada-Bouzid, E., Bertucci, F., Bompas, E., Alexandre, J., Collard, O., Lebrun-Ly, V., Soulier, P., Toulmonde, M., Le Cesne, A., Lacas, B., and Duffaud, F.

Published
2021
Full Text
View/download PDF

7. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial †

Author

Clement, PM, Gauler, T, Machiels, JP, Haddad, RI, Fayette, J, Licitra, LF, Tahara, M, Cohen, EEW, Cupissol, D, Grau, JJ, Guigay, J, Caponigro, F, de Castro, G, de Souza Viana, L, Keilholz, U, del Campo, JM, Cong, XJ, Ehrnrooth, E, and Vermorken, JB

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Dental/Oral and Craniofacial Disease, Cancer, Clinical Trials and Supportive Activities, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Afatinib, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Disease-Free Survival, Female, Head and Neck Neoplasms, Humans, Male, Methotrexate, Neoplasm Metastasis, Neoplasm Recurrence, Local, Platinum, Quinazolines, Squamous Cell Carcinoma of Head and Neck, Treatment Outcome, LUX-H&N 1 investigators, HNSCC, afatinib, methotrexate, older, phase III, second-line, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundIn the phase III LUX-Head & Neck 1 (LHN1) trial, afatinib significantly improved progression-free survival (PFS) versus methotrexate in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients progressing on/after platinum-based therapy. This report evaluates afatinib efficacy and safety in prespecified subgroups of patients aged ≥65 and

Published
2016

8. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck †

Author

Seiwert, TY, Fayette, J, Cupissol, D, del Campo, JM, Clement, PM, Hitt, R, Degardin, M, Zhang, W, Blackman, A, Ehrnrooth, E, and Cohen, EEW

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Cancer, Rare Diseases, Dental/Oral and Craniofacial Disease, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Afatinib, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Carcinoma, Squamous Cell, Cetuximab, ErbB Receptors, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Quinazolines, Receptor, ErbB-2, Squamous Cell Carcinoma of Head and Neck, Treatment Outcome, Young Adult, afatinib, cetuximab, recurrent HNSCC, metastatic HNSCC, EGFR inhibitor therapy, Receptor, erbB-2, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundAfatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the agent would have greater antitumor activity compared with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients, whose disease has progressed after platinum-containing therapy.Patients and methodsAn open-label, randomized, phase II trial was conducted in 43 centers; 124 patients were randomized (1 : 1) to either afatinib (50 mg/day) or cetuximab (250 mg/m(2)/week) until disease progression or intolerable adverse events (AEs) (stage I), with optional crossover (stage II). The primary end point was tumor shrinkage before crossover assessed by investigator (IR) and independent central review (ICR).ResultsA total of 121 patients were treated (61 afatinib, 60 cetuximab) and 68 crossed over to stage II (32 and 36 respectively). In stage I, mean tumor shrinkage by IR/ICR was 10.4%/16.6% with afatinib and 5.4%/10.1% with cetuximab (P = 0.46/0.30). Objective response rate was 16.1%/8.1% with afatinib and 6.5%/9.7% with cetuximab (IR/ICR). Comparable disease control rates were observed with afatinib (50%) and cetuximab (56.5%) by IR; similar results were seen by ICR. Most common grade ≥3 drug-related AEs (DRAEs) were rash/acne (18% versus 8.3%), diarrhea (14.8% versus 0%), and stomatitis/mucositis (11.5% versus 0%) with afatinib and cetuximab, respectively. Patients with DRAEs leading to treatment discontinuation were 23% with afatinib and 5% with cetuximab. In stage II, disease control rate (IR/ICR) was 38.9%/33.3% with afatinib and 18.8%/18.8% with cetuximab.ConclusionAfatinib showed antitumor activity comparable to cetuximab in R/M HNSCC in this exploratory phase II trial, although more patients on afatinib discontinued treatment due to AEs. Sequential EGFR/ErbB treatment with afatinib and cetuximab provided sustained clinical benefit in patients after crossover, suggesting a lack of cross-resistance.

Published
2014

9. Characterization of a Molecularly Distinct Subset of Oncocytic Pleomorphic Adenomas/Myoepitheliomas Harboring Recurrent ZBTB47-AS1::PLAG1Gene Fusion

Author

Alsugair, Ziyad, Perrot, Jimmy, Descotes, Françoise, Lopez, Jonathan, Champagnac, Anne, Pissaloux, Daniel, Castain, Claire, Onea, Mihaela, Céruse, Philippe, Philouze, Pierre, Lépine, Charles, Lanic, Marie-Delphine, Laé, Marick, Costes-Martineau, Valérie, Benzerdjeb, Nazim, Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Grayeli, A. Bozorg, Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Clatot, F., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F. R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Saint Guily, J. Lacau, Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Cardon, A. Lasne, Le Tourneau, C., Lefebvre, G, Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A, Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Dang, N. Pham, Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., Prades, J.-M., Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., Thariat, J., David, M. Timar, Timochenko, A., Toussaint, B., Coste, E. Uro, Valette, G., Van den Abbele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., and Wong, S.

Abstract

Recurrent gene fusions are common in salivary gland tumors including benign tumors, such as pleomorphic adenoma (PA) and myoepithelioma (ME). In cases where chromosomal rearrangement is identified in the pleomorphic adenoma gene 1 (PLAG1)gene, different gene partners are found. Oncocytic metaplasia, characterized by oncocytes with abundant eosinophilic granular cytoplasm and hyperchromatic nuclei, is a well-known phenomenon in salivary gland neoplasms. However, the pure oncocytic variant of PA/ME showed PLAG1gene rearrangements involving various gene partners at the molecular level, without any recurrent fusion being found. Our study includes 20 cases of PA/ME, with 11 females and 9 males. The age of patients ranged from 37 to 96 years, with a median age of 62.8 years. Most tumors originate from the parotid gland. The median size of the tumor was 26.5 mm (range: 13 to 60 mm). Among the 20 cases, 14 were a pure oncocytic variant of PA/ME, whereas 6 cases showed focal oncocytic or oncocytic-like aspects. Molecular studies on 20 cases of PA/ME were conducted. A novel recurrent ZBTB47-AS1::PLAG1fusion was identified in 6 of 12 cases with pure oncocytic metaplasia, whereas the other cases had PLAG1gene fusion with different gene partners. The transcriptomic analysis of the cases harboring ZBTB47-AS1::PLAG1fusion demonstrated that these tumors have a distinct molecular profile from conventional PA/ME. This study reveals a unique subset in the oncocytic PA/ME spectrum characterized by pure oncocytic morphology with larger oncocytic cells and recurrent ZBTB47-AS1::PLAG1fusion. It also highlights the transcriptomic distinctness of salivary gland adenomas with pure oncocytic metaplasia in the spectrum of salivary gland neoplasms. Further studies are needed to better understand the oncocytic variant of PA/ME and to determine the true nature of oncocytic cells in PA/ME.

Published
2024
Full Text
View/download PDF

10. Improved survival using specialized multidisciplinary board in sarcoma patients

Author

Blay, J.-Y., Soibinet, P., Penel, N., Bompas, E., Duffaud, F., Stoeckle, E., Mir, O., Adam, J., Chevreau, C., Bonvalot, S., Rios, M., Kerbrat, P., Cupissol, D., Anract, P., Gouin, F., Kurtz, J. -E., Lebbe, C., Isambert, N., Bertucci, F., Toumonde, M., Thyss, A., Piperno-Neumann, S., Dubray-Longeras, P., Meeus, P., Ducimetière, F., Giraud, A., Coindre, J. -M., Ray-Coquard, I., Italiano, A., and Le Cesne, A.

Published
2017
Full Text
View/download PDF

11. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database

Author

Salas, S., Resseguier, N., Blay, J.Y., Le Cesne, A., Italiano, A., Chevreau, C., Rosset, P., Isambert, N., Soulie, P., Cupissol, D., Delcambre, C., Bay, J.O., Dubray-Longeras, P., Krengli, M., De Bari, B., Villa, S., Kaanders, J.H.A.M., Torrente, S., Pasquier, D., Thariat, J.O., Myroslav, L., Sole, C.V., Dincbas, H.F., Habboush, J.Y., Zilli, T., Dragan, T., Khanfir, K., Ugurluer, G., Cena, T., Duffaud, F., Penel, N., Bertucci, F., Ranchere-Vince, D., Terrier, P., Bonvalot, S., Macagno, N., Lemoine, C., Lae, M., Coindre, J.M., and Bouvier, C.

Published
2017
Full Text
View/download PDF

14. Traitements locorégionaux de métastase(s) cérébrale(s) chez des patients atteints d’un mélanome cutané métastatique : recommandations nationales françaises

Author

Lubrano, V., Derrey, S., Truc, G., Mirabel, X., Thariat, J., Cupissol, D., Sassolas, B., Combemale, P., Modiano, P., Bedane, C., Dygai-Cochet, I., Lamant, L., Mourrégot, A., Rougé Bugat, M.-È., Siegrist, S., Tiffet, O., Mazeau-Woynar, V., Verdoni, L., Planchamp, F., and Leccia, M.-T.

Published
2014
Full Text
View/download PDF

17. 123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Author

Colevas, D.A., primary, Misiukiewicz, K., additional, Pearson, A.T., additional, Fayette, J., additional, Bauman, J.R., additional, Cupissol, D., additional, Saada-Bouzid, E., additional, Adkins, D.R., additional, Marie, D.B., additional, Cornen, S.L., additional, André, P., additional, Carrette, F., additional, Rotolo, F., additional, Boyer Chammard, A., additional, and Cohen, R.B., additional

Published
2021
Full Text
View/download PDF

18. Traitements systémiques de première et de deuxième lignes des patients atteints d’un mélanome cutané métastatique (hors métastase cérébrale) : Recommandations nationales françaises

Author

Cupissol, D., Sassolas, B., Combemale, P., Modiano, P., Bedane, C., Derrey, S., Dygai-Cochet, I., Lamant, L., Lubrano, V., Mirabel, X., Mourrégot, A., Rougé Bugat, M. -E., Siegrist, S., Thariat, J., Tiffet, O., Truc, G., Verdoni, L., Mazeau-Woynar, V., Planchamp, F., and Leccia, M. T.

Published
2014
Full Text
View/download PDF

20. LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study

Author

Pautier, P., primary, Italiano, A., additional, Piperno-Neumann, S., additional, Chevreau, C.M., additional, Penel, N., additional, Cupissol, D., additional, Boudou Rouquette, P., additional, Bertucci, F., additional, Balleyguier, C., additional, Lebrun-Ly, V., additional, Blay, J-Y., additional, Kalbacher, E., additional, Delcambre, C., additional, Bompas, E., additional, Collard, O., additional, Isambert, N., additional, Guillemet, C., additional, Rios, M., additional, Sundqvist, M., additional, and Duffaud, F., additional

Published
2021
Full Text
View/download PDF

21. LBA58 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer

Author

Duffaud, F., primary, Chabaud, S., additional, Chevreau, C.M., additional, Italiano, A., additional, Perrin, C., additional, Isambert, N., additional, Piperno-Neumann, S., additional, Saada-Bouzid, E., additional, Bertucci, F., additional, Cupissol, D., additional, Kalbacher, E., additional, Narciso, B., additional, Schiffler, C., additional, de Sousa Carvalho, N., additional, Monard, L., additional, Bouvier, C., additional, Vidal, V., additional, Blay, J-Y., additional, and Mir, O., additional

Published
2021
Full Text
View/download PDF

22. 916P Impact of sarcopenia (S) on efficacy and toxicity of nivolumab (N) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study

Author

Muratori, L., primary, Texier, M., additional, Mayache-Badis, L., additional, Bidault, F., additional, Iacob, M., additional, Daste, A., additional, Fayette, J., additional, Lefebvre, G., additional, Saada-Bouzid, E., additional, Zanetta, S., additional, Toullec, C., additional, Cupissol, D., additional, Salas, S., additional, Kaminsky-Forrett, M-C., additional, Johnson, A.C., additional, Ferrand, F.R., additional, Aupérin, A., additional, Guigay, J., additional, Raynard, B., additional, and Even, C., additional

Published
2021
Full Text
View/download PDF

23. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

Author

Guigay, J, Auperin, A, Fayette, J, Saada-Bouzid, E, Lafond, C, Taberna, M, Geoffrois, L, Martin, L, Capitain, O, Cupissol, D, Castanie, H, Vansteene, D, Schafhausen, P, Johnson, A, Even, C, Sire, C, Duplomb, S, Evrard, C, Delord, JP, Laguerre, B, Zanetta, S, Chevassus-Clement, C, Fraslin, A, Louat, F, Sinigaglia, L, Keilholz, U, Bourhis, J, Mesia, R, Gallego, O, López Pousa A., and Vazquez Fernandez, Silvia

Abstract

Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel-platinum-cetuximab) showed promising results, with a median overall survival of 14.0 months in first-line recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). We therefore aimed to compare the efficacy and safety of the TPEx regimen with the standard of care EXTREME regimen (platinum-fluorouracil-cetuximab) in this setting. Methods This was a multicentre, open-label, randomised, phase 2 trial, done in 68 centres (cancer centres, university and general hospitals, and private clinics) in France, Spain, and Germany. Eligible patients were aged 18-70 years with histologically confirmed recurrent or metastatic HNSCC unsuitable for curative treatment; had at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1; and had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less. Participants were randomly assigned (1:1) using the TenAlea website by investigators or delegated clinical research associates to the TPEx regimen or the EXTREME regimen, with minimisation by ECOG performance status, type of disease evolution, previous cetuximab treatment, and country. The TPEx regimen consisted of docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2), both intravenously on day 1, and cetuximab on days 1, 8, and 15 (intravenously 400 mg/m(2) on day 1 of cycle 1 and 250 mg/m(2) weekly subsequently). Four cycles were repeated every 21 days with systematic granulocyte colony-stimulating factor (G-CSF) support at each cycle. In case of disease control after four cycles, intravenous cetuximab 500 mg/m(2) was continued every 2 weeks as maintenance therapy until progression or unacceptable toxicity. The EXTREME regimen consisted of fluorouracil 4000 mg/m(2) on day 1-4, cisplatin 100 mg/m(2) on day 1, and cetuximab on days 1, 8, and 15 (400 mg/m(2) on day 1 of cycle 1 and 250 mg/m(2) weekly subsequently) all delivered intravenously. Six cycles were delivered every 21 days followed by weekly 250 mg/m(2) cetuximab as maintenance therapy in case of disease control. G-CSF support was not mandatory per the protocol in the EXTREME regimen. The primary endpoint was overall survival in the intention-to-treat population; safety was analysed in all patients who received at least one dose of chemotherapy or cetuximab. Enrolment is closed and this is the final analysis. This study is registered at ClinicalTrials.gov, NCT02268695. Findings Between Oct 10, 2014, and Nov 29, 2017, 541 patients were enrolled and randomly assigned to the two treatment regimens (271 to TPEx, 270 to EXTREME). Two patients in the TPEx group had major deviations in consent forms and were not included in the final analysis. Median follow-up was 34.4 months (IQR 26.6-44.8) in the TPEx group and 30.2 months (25.5-45.3) in the EXTREME group. At data cutoff, 209 patients had died in the TPEx group and 218 had died in the EXTREME group. Overall survival did not differ significantly between the groups (median 14.5 months [95% CI 12.5-15.7] in the TPEx group and 13.4 months [12.2-15.4] in the EXTREME group; hazard ratio 0.89 [95% CI 0.74-1.08]; p=0.23). 214 (81%) of 263 patients in the TPEx group versus 246 (93%) of 265 patients in the EXTREME group had grade 3 or worse adverse events during chemotherapy (p

Published
2021

26. 81P Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from a phase II trial

Author

Fayette, J., primary, Bauman, J., additional, Salas, S., additional, Colevas, D., additional, Even, C., additional, Cupissol, D., additional, Posner, M.R., additional, Lefebvre, G., additional, Saada-Bouzid, E., additional, Bernadach, M., additional, Seiwert, T., additional, Pearson, A., additional, Messouak, S., additional, Cornen, S.L., additional, Andre, P., additional, Rotolo, F., additional, Boyer-Chammard, A., additional, and Cohen, R.B., additional

Published
2020
Full Text
View/download PDF

31. 946P Germinal immunogenetics and response to nivolumab in recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC) patients (pts): TopNIVO ancillary study

Author

Saada, E.B., primary, Koudou, Y., additional, Daste, A., additional, Fayette, J., additional, Lefebvre, G., additional, Zanetta, S., additional, Toullec, C., additional, Cupissol, D., additional, Salas, S., additional, Kaminsky-Forrett, M-C., additional, Johnson, A.C., additional, Vauleon, E., additional, Ebran, N., additional, Schmidt, M., additional, Texier, M., additional, Peyrade, F., additional, Milano, G., additional, Guigay, J., additional, Even, C., additional, and Etienne-Grimaldi, M-C., additional

Published
2020
Full Text
View/download PDF

32. 917MO TOPNIVO - A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): Final analysis

Author

Even, C., primary, Daste, A., additional, Fayette, J., additional, Lefebvre, G., additional, Saada-Bouzid, E., additional, Zanetta, S., additional, Toullec, C., additional, Cupissol, D., additional, Salas, S., additional, Kaminski, M.C., additional, Johnson, A.C., additional, Vauleon, E., additional, Le Tourneau, C., additional, Sire, C., additional, Prevost, A., additional, Jallut, I., additional, Bourhis, J., additional, Guigay, J., additional, Aupérin, A., additional, and Texier, M., additional

Published
2020
Full Text
View/download PDF

33. 970P MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with docetaxel, cisplatin and 5-FU (DCF) as induction therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Author

Even, C., primary, Texier, M., additional, Le Tourneau, C., additional, Bahleda, R., additional, Borcoman, E., additional, Vinches, M., additional, Toussaint, P., additional, Marabelle, A., additional, Breuskin, I., additional, Cupissol, D., additional, and Fayette, J., additional

Published
2020
Full Text
View/download PDF

36. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)

Author

Pautier, P., primary, Penel, N., additional, Ray-Coquard, I., additional, Italiano, A., additional, Bompas, E., additional, Delcambre, C., additional, Bay, J.-O., additional, Bertucci, F., additional, Delaye, J., additional, Chevreau, C., additional, Cupissol, D., additional, Bozec, L., additional, Eymard, J.-C., additional, Saada, E., additional, Isambert, N., additional, Guillemet, C., additional, Rios, M., additional, Piperno-Neumann, S., additional, Chenuc, G., additional, and Duffaud, F., additional

Published
2020
Full Text
View/download PDF

37. What is the best management for a spermatic cord sarcoma in 2018?

Author

Carrere, S., Tetreau, R., Honore, C., Tzanis, D., Delhorme, J.-B., Fau, M., Decanter, G., Llacer, C., Firmin, N., Stoeckle, E., Méeus, P., Ferron, G., Cupissol, D., Quenet, F., Meunier, B., Bonvalot, S., Institut du Cancer de Montpellier (ICM), Institut Gustave Roussy (IGR), Institut Curie [Paris], Hôpital de Hautepierre [Strasbourg], Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Bergonié [Bordeaux], Centre Léon Bérard [Lyon], Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), and CHU Pontchaillou [Rennes]

Subjects
Adult, Male, Spermatic Cord, Soft tissue sarcoma, Urologic Surgical Procedures, Male, Pluridisciplinarité, [SDV]Life Sciences [q-bio], Sarcoma, Prognosis, Quality, Sarcome du cordon spermatique, Diagnosis, Differential, Young Adult, Sarcome des tissus mous, Mulidisciplinarity, Genital Neoplasms, Male, Humans, Surgery, Child, Chirurgie, Spermatic cord sarcoma, Qualité, Aged
Abstract

International audience; Spermatic cord sarcomas are rare tumors for which the most important is the initial diagnostic procedure. They are frequently misdiagnosed after surgery for inguinal hernia, inguinal lymphadenectomy or testicular malignancy. Any clinical suspicion has to lead to perform imaging with MRI and a core needle biopsy in order to obtain an accurate preoperative diagnosis. Liposarcoma and leiomyosarcoma are the most common histological subtypes in elderly adults, rhabdomyosarcoma in children or in young adults. A CT scan will precede the treatment in order to look for distant metastasis and abdominal involvement. The therapeutic strategy as well as the surgical planning are then adapted to the histological, morphological and prognostic factors. Surgery is the cornerstone for the treatment of spermatic cord sarcoma. The minimum requirements for the surgical procedure are a wide excision of the tumor en bloc with radical orchidectomy, excision of the ipsilateral scrotum and high spermatic cord ligation. It could be enlarged to the anterior abdominal wall and adjacent organs some required a soft tissue flap. Spermatic cord sarcoma and trunk wall sarcoma have the same prognosis for which local recurrence could significantly decrease survival. Consequently, surgeon in charge with these tumors has to be familiar with soft tissue sarcoma and the management of these patients must be carried out under the supervision of a multidisciplinary team within the Netsarc network.; Le sarcome du cordon spermatique est une pathologie rare pour laquelle la prise en charge initiale est d’importance primordiale. Le diagnostic est souvent découvert a posteriori après une chirurgie pour cure de hernie inguinale, pour suspicion de cancer du testicule ou après exérèse d’une adénopathie inguinale. Toute suspicion clinique doit donc faire l’objet d’une imagerie par résonance magnétique (IRM) et d’une biopsie percutanée sous contrôle radiologique dans le but d’obtenir un diagnostic préopératoire précis. Les histologies les plus fréquentes sont le liposarcome et le léiomyosarcome chez l’adulte âgé, le rhabdomyosarcome chez l’enfant et l’adulte jeune. Un bilan d’extension intra-abdominal et à distance par scanner précédera le traitement. La stratégie thérapeutique de même que la planification chirurgicale sont ensuite adaptées aux paramètres histologiques, morphologiques et pronostiques. La chirurgie est la pierre angulaire du traitement des sarcomes du cordon spermatique. Le geste minimal requis est l’exérèse de la tumeur en bloc avec la réalisation d’une orchidectomie totale, l’exérèse du cordon spermatique et la ligature des vaisseaux spermatiques à l’orifice inguinal profond. Elle peut être élargie à la paroi abdominale et aux organes de voisinage et nécessiter si besoin une reconstruction par lambeau. Le pronostic des sarcomes du cordon spermatique est équivalent à celui des sarcomes du tronc dont l’évolutivité locale est péjorative pour la survie des patients. De fait, l’exérèse doit être réalisée par un chirurgien ayant l’expertise des problématiques liées à la chirurgie des sarcomes au sein d’un centre spécialisé du réseau Netsarc.

Published
2019

42. [Reprint of: Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie]

Author

Guillot, B., Charles, Jérôme, Jeudy, G., Cupissol, D., Dupuy, A., Dutriaux, C., Gangloff, D., Magné, N., Mirabel, X., M'Sadek, A., Pracht, M., Sichel, C., Do Outeiro, G., Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Grenoble, Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CRLCC Val d'Aurelle - Paul Lamarque, CHU Pontchaillou [Rennes], CHU Bordeaux [Bordeaux], Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Cancérologie Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, CRLCC Eugène Marquis (CRLCC), Institut National du Cancer [Boulogne Billancourt] (INC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Etienne, and Université Lille Nord de France (COMUE)-UNICANCER

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

43. Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials

Author

Guigay, J., primary, Auperin, A., additional, Mertens, C., additional, Even, C., additional, Geoffrois, L., additional, Cupissol, D., additional, Rolland, F., additional, Sire, C., additional, Fayette, J., additional, Peyrade, F., additional, Blot, E., additional, Debourdeau, P., additional, Bozec, L., additional, Capitain, O., additional, Pointreau, Y., additional, Brard, C., additional, Michel, C., additional, Schwob, D., additional, Ortholan, C., additional, and Le Caer, H., additional

Published
2019
Full Text
View/download PDF

44. Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial

Author

Fayette, J., primary, Digue, L., additional, Ségura-Ferlay, C., additional, Treilleux, I., additional, Wang, Q., additional, Lefebvre, G., additional, Daste, A., additional, Even, C., additional, Couchon Thaunat, S., additional, Guyennon, A., additional, Peyrade, F., additional, Cupissol, D., additional, You, B., additional, Le Tourneau, C., additional, Jaouen, L., additional, Grinand, E., additional, Tabone-Eglinger, S., additional, Garin, G., additional, and Perol, D., additional

Published
2019
Full Text
View/download PDF

45. Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study)

Author

Marabelle, A., primary, Ghiringhelli, F., additional, Ayyoub, M., additional, Tartour, E., additional, Adotevi, O., additional, Loriot, Y., additional, Lambotte, O., additional, Cupissol, D., additional, Damotte, D., additional, Adam, J., additional, Bonvalet, M., additional, Petre Lazar, B., additional, Licour, M., additional, and Chaput, N., additional

Published
2018
Full Text
View/download PDF

47. Final report of the French Multicenter Phase II Study of the Nitrosourea Fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases

Author

Jacquillat, C., Khayat, D., Banzet, P., Weil, M., Fumoleau, P., Avril, M.-F., Namer, M., Bonneterre, J., Kerbrat, P., Bonerandi, J.J., Bugat, R., Montcuquet, P., Cupissol, D., Lauvin, R., Vilmer, C., Prache, C., and Bizzari, J.P.

Subjects
Melanoma -- Drug therapy, Chemotherapy -- Physiological aspects, Health
Abstract

The effectiveness of nitrosourea fotemustine in treating malignant melanoma, which is an aggressive tumor of melanocytes, pigmented skin cells, was assessed in 169 afflicted patients. The cancer was disseminated throughout the body, including the brain. Nitrosourea fotemustine was given in a dose of 100 milligrams per square meter of body area by intravenous infusion over a one-hour period, every week for three weeks. This was followed by a rest period of four to five weeks. Therapy was maintained at the same dose every three weeks in patients who responded or were stabilized by initial treatment, until their disease progressed. Of 169 patients treated, 153 were assessed for complete response, as indicated by the elimination of the tumor. Treatment with nitrosourea fotemustine resulted in complete responses in three cases and partial responses in 34 patients, thereby producing a response rate of 24.2 percent. The response rates at specific sites were 25 percent within the brain; 19.2 percent in the viscera (or abdominal region); and 31.8 percent at nonvisceral sites. In most cases, the duration of response was 22 weeks, and the response rate in previously untreated patients was 30.7 percent. The main toxic effects of nitrosourea fotemustine were blood-related, and included leukopenia (an abnormal decrease in white blood cells) and thrombocytopenia (an abnormal decrease in platelets, cells involved in blood clotting). These findings suggest that nitrosourea fotemustine is effective and relatively safe in treating disseminated malignant melanoma. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

48. TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC

Author

Even, C., primary, Daste, A., additional, Saada-Bouzid, E., additional, Fayette, J., additional, Kaminsky-Forrett, M.-C., additional, Zanetta, S., additional, Prevost, A., additional, Lefebvre, G., additional, Borel, C., additional, Cupissol, D., additional, Huguet, F., additional, Delord, J.-P., additional, Baste Rotllan, N., additional, Delaye, J., additional, Jallut, I., additional, Vintonenko, N., additional, Bourhis, J., additional, Guigay, J., additional, Texier, M., additional, and Auperin, A., additional

Published
2018
Full Text
View/download PDF

49. Republication de : Traitements des patients atteints de mélanome de stade III inopérable ou de stade IV. Société française de dermatologie

Author

Guillot, B., primary, Charles, J., additional, Jeudy, G., additional, Cupissol, D., additional, Dupuy, A., additional, Dutriaux, C., additional, Gangloff, D., additional, Magne, N., additional, Mirabel, X., additional, M'Sadek, A., additional, Pracht, M., additional, Sichel, C., additional, and Do Outeiro, G., additional

Published
2018
Full Text
View/download PDF

50. Traitements des patients atteints de mélanome de stade III inopérable ou de stade IV. Société française de dermatologie

Author

Guillot, B., primary, Charles, J., additional, Jeudy, G., additional, Cupissol, D., additional, Dupuy, A., additional, Dutriaux, C., additional, Gangloff, D., additional, Magne, N., additional, Mirabel, X., additional, M'Sadek, A., additional, Pracht, M., additional, Sichel, C., additional, and Do Outeiro, G., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results